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ABSTRACT

This study aimed to determine if a dietary intervention of fish oil could reduce the risk of
metabolic syndrome phenotype associated with glucocorticoids (GC), given as part of the
acute lymphocytic leukemia (ALL) treatment. Weaned C57BL/6 male mice were
assigned either a standard rodent chow or Western-type diets containing 45% calories
from fat consisting of lard (high omega-6/low omega-3 fatty acids). At six weeks of age,
GC treatment was given daily for 28 days to half the mice in each diet group. Mice on the
lard diet either remained on this diet or were switched to an isocaloric diet containing
45% fat from fish oil (high omega-3/low omega-6 fatty acids). Our data showed that the
fish oil diet (high in omega-3 fatty acids) reduced body mass gain, fatty liver
development, and glucose tolerance when used in combination with high dose GC
therapy. The data suggests that consuming more omega-3 fatty acids than omega-6 fatty
acids might reduce the metabolic syndrome phenotype associated with ALL treatment.
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BACKGROUND
Pediatric acute lymphoblastic leukemia (ALL) constitutes 30% of all childhood
malignancies in the United States, making it the most common form of childhood
cancer.1 This cancer originates with abnormal white blood cell (lymphoblast)
accumulation in the bone marrow and blood.1,2 The current event-free survival rate is
now 75%-85% for patients diagnosed with pediatric ALL.2 However, despite a very
successful cancer treatment, these survivors have multiple long term negative health
consequences that are associated with an increase in body mass. These detrimental side
effects resemble metabolic syndrome and comprise of specific symptoms of abdominal
obesity, impaired glucose tolerance, high blood pressure, elevated triglyceride levels, low
high-density lipoprotein (HDL) levels, and recently added, non-alcoholic fatty liver
disease (NAFLD).
The standard treatment protocol for ALL includes multiple chemotherapeutic
agents and high dose glucocorticoids. During the induction phase (first 28 days of
therapy) patients receive Vincristine, Daunorubicin, PEG-Asparaginase,
Cyclophosphamide, Cytarabine, and Mercaptopurine along with approximately 40
mg/m2/day of synthetic glucocorticoids, specifically Prednisone.3
It is well known that chronic glucocorticoid treatment alters metabolic programs
favoring weight gain.4 During ALL treatment most weight gain occurs during the
induction phase of treatment during which time high doses of the synthetic
glucocorticoid, Prednisone/Prednisolone, is administered. This suggests that the treatment
contributes to the metabolic syndrome phenotype associated with ALL therapy.5
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Glucocorticoids (GCs) are stress hormones naturally secreted by the adrenal
cortex to help decrease inflammation and control energy metabolism. As stated above,
certain GCs such as Prednisone/Prednisolone are part of the chemotherapy treatment
protocol of pediatric ALL.6 Prednisone/Prednisolone is typically used for its antiinflammatory and cytolytic effect on thymocytes and therefore, is essential in treatment
because of the dramatic increase in immature thymocytes as well as
chemotherapy-induced inflammation seen during pediatric ALL.7 Synthetic GCs are
shown to cause massive cell death, or apoptosis, in lymphoid malignant cells by
transcriptionally regulating and altering a variety of different genes.8 GCs bind to ligandactivated zinc finger transcription factors called glucocorticoid receptors (GRs) found in
the cytosol of the cell. After binding to GRs, GCs move to the nucleus and function as a
DNA sequence-specific transcriptional regulator of certain GC-responsive target genes.9
These target genes are shown to help control hepatic energy metabolism, especially
protein and sugar homeostasis.4
Sugar homeostasis is the balance of insulin and glucagon to maintain steady
ranges of blood glucose levels. When blood glucose is high, insulin is secreted by the
pancreatic beta cells to facilitate the transport of glucose into the cells for energy. During
a fasted state or prolonged exercise, glucagon from the alpha cells of the pancreas and
natural GCs are released to simulate catabolic reactions in the body by antagonizing
anabolic insulin actions.4 However, a chronic increase of natural or synthetic GCs can
alter certain processes causing an increase in anti-inflammatory molecules and
gluconeogenic enzyme levels such as an increase in phosphoenolpyruvate carboxykinase
(PEPCK). An increase in these gluconeogenic enzyme levels causes the body to use non-
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carbohydrate precursors to make glucose, which causes an increase in blood glucose
levels. Other alterations caused by GCs can lead to the inhibition of glucose uptake into
muscle and adipose tissue as well as increased adipose tissue lipolysis to generate fatty
acids as an energy source for muscles. These alterations promote a further rise in blood
glucose levels and eventually insulin resistance or type 2 Diabetes Mellitus.4 Free Fatty
acids have been shown to be elevated in obese individuals due to enlarged adipose tissue
that releases more free fatty acids. Free fatty acids can cause an increase in blood glucose
by inhibiting insulin’s anti-lipolytic action, leading to an increase in the rate of free fatty
acids into circulation. 10 Furthermore, an increase in free fatty acids can increase the
secretion of glucagon, and therefore, gluconeogenesis and high levels of glucose in the
blood. 11
Although acute exposure of GCs increases lipolysis in adipose tissue, chronic use
of GCs can lead to an increase in total mass of adipose tissue, especially in conjunction
with a high fat diet (HFD) that is low in omega-3 polyunsaturated fatty acids (n-3).12,13
Increases in adipose tissue may be caused by the redistribution of fat from peripheral to
central and visceral depots leading to further deregulation of the metabolism. Most
pediatric patients with ALL, as well as patients with Cushing’s syndrome, have fat
redistribution as a common phenotype. The shared feature between these two types of
patients is chronically increased GCs of either natural or synthetic origins, with the
naturally increased GC levels occurring due to irregular hormonal and metabolic
processes and stress responses.4,14
Changes in fat distribution are not the only issues with chronic exposure to GCs.
Although GCs are known for their anti-inflammatory activity, long-term use tends to
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promote other inflammatory issues that stimulates steatosis of the liver.15 Chronically
elevated GC levels alter the regulation of liver processes which can cause increased
triglyceride synthesis, decreased fatty acid oxidation, and increased accumulation of
lipids, leading to fatty liver.16
Long-term deregulation of hepatic processes is detrimental as the liver is
responsible for the control of glucose and lipid homeostasis. Untreated liver disease can
result in liver failure and even death.17 Non-alcoholic fatty liver disease (NAFLD) is a
chronic inflammatory condition that can range from simple steatosis, also called simple
fatty liver, to nonalcoholic steatohepatitis (NASH). NASH can later progress into more
advanced inflammatory stages such as fibrosis, cirrhosis, hepatic apoptosis, and
hepatocellular carcinoma.18 Fatty liver results from the accumulation of triglycerides in
the cells due to an increased uptake of free fatty acids and de novo liponeogenesis in the
hepatocytes while also exhibiting a decreased secretion of very low density lipoprotein
cholesterol (VLDL-C) out of the liver.19 GCs alter the transcriptional regulation of many
different metabolic genes and enzymes such as glucose-6-phosphatase (G6Pase) and
PEPCK. These alterations have an immense effect on how macronutrients are
metabolized and stored in the body. However, the entire effect of GC treatment in
concurrence with a HFD on hepatic inflammation and fibrosis remains unclear. There is
some evidence that a HFD of about 60% of calories in conjunction with GCs rapidly
induces the development of fatty liver disease. In addition to the production of fatty liver
disease, there is lipid spillover from central adipose tissue, which rapidly promotes
insulin deregulation leading to the diabetic phenotype and hepatic insulin resistance.15
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Conversely, studies have found positive effects of a HFD that is high in n-3 fatty
acids on improved liver outcomes such as a decrease in hepatic steatosis, inflammation
and necrosis.20 Omega-3 fatty acids have been shown to be safe and effective for the
treatment of fatty liver disease by improving hypertriglyceridemia and down regulating
leptin and resistin levels and upregulating adiponectin expression.20,21 In turn, increased
adiponectin levels are associated with decreased liver inflammation and fibrosis as well
as decreased hepatic and systematic insulin resistance.22
Insulin resistance, also known as Type 2 Diabetes Mellitus, can be a consequence
of chronic liver disease, especially in the presence of hyperlipidemia. Insulin lowers
blood glucose and inhibits lipolysis. Therefore, hyperlipidemia in combination with
insulin resistance favors an increase in fat mass and lipolysis, causing elevated levels of
free fatty acids and therefore, a further decrease in the effectiveness of insulin signals.
The reduced insulin signaling causes hyperglycemia, which leads to elevated hepatic
glucose, up regulation of de novo liponeogenesis, and a further increase in free fatty
acids.23 The rise of free fatty acids causes an escalation of oxidative stress, fatty liver
disease, and increase in adipose tissue. Insulin resistance and the accumulation of
adipokines, such as leptin and the pro-inflammatory cytokines, Tumor Necrosis Factor
alpha (TNF-α) and interleukin 6 (IL-6), exacerbate the oxidative stress and perpetuate the
liver inflammation leading to further liver damage.24
TNF-α is released by adipose tissue associated macrophages (ATMs).25 Previous
work demonstrated that an increase in GCs causes adipocyte hypertrophy and thereby
increases pro-inflammatory TNF-α secretion.26 TNF-α is an inhibitor of the GLUT4
insulin signal through its influence on the tyrosine kinase activity of the insulin receptor,
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thus causing a prevention of glucose uptake in the cells.25 Therefore, GCs may cause
insulin resistance as a result of the increased release of TNF-α from hypertrophied
adipocytes. This accounts for increased TNF-α serum levels that are present during
obesity and hyperinsulinemia.27
Another component of weight management is the hormone leptin. This hormone
is responsible for the regulation of energy balance through the suppression of appetite in
order to reduce food intake. 28 Increased leptin, along with decreased adiponectin, has
been shown to be connected with amplified severity of steatosis and fibrosis of the liver
and increased occurrence of insulin resistance.29 Previous animal studies have shown that
n-3 treatment can cause a decrease in leptin and resistin levels in serum and adipose
tissue, while increasing the adipokine, adiponectin, over time.20 Adiponectin expression
can be inhibited by both GCs and the pro-inflammatory cytokine TNF-α.26 Excess TNF-α
and leptin hormone has also been shown to impair insulin resistance by inducing insulin
resistance in pancreatic β cells by stimulating the release of mediators that are toxic for
these cells.30,31
These factors that cause insulin resistance and NAFLD can cause patients to
experiences signs and symptoms of NAFLD such as malaise, fatigue, right upper
quadrant pain, abdominal discomfort, hepatomegaly, jaundice, ascites, and indications of
metabolic syndrome. However, most cases of NAFLD can appear as asymptomatic, and
therefore, biomarkers are useful to assess liver status including aspartate- and alanine
aminotransferase levels (ALT), total and direct bilirubin, fasting serum glucose, and lipid
panel.15
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While the liver and the pancreas are key regulatory organs of metabolism, other
important and less studied organs are the small and large intestines. Former studies have
shown that GCs may play a role in the increased intestinal uptake of glucose, which may
contribute to the development of hyperglycemia in patients on chronic GC therapy.32
There are a variety of sugar transporters in the intestine including GLUT2, GLUT5,
GLUT7, GLUT9, and sodium-dependent glucose co-transporter (SGLT1).33 The variety
is indicative of adaptation of the intestinal sugar transport system depending on the
different dietary proportions of macronutrients consumed.34 Although there is limited
evidence on how these transporters function during digestion, carbohydrates in the
intestine require absorption by a two-step, two-membrane-transport process. The SGLT1
and the facilitative fructose transporter, GLUT5, in the brush border membrane lining the
intestinal lumen35 absorb monosaccharides, GLUT2 is a facilitative transporter of both
glucose and fructose in the basolateral membrane of the small intestine and is activated
by glucose transport through SGLT1.36, 37
During postnatal small intestinal development specific GCs have been shown to
regulate cytokine gene expression. This suggests that cytokines may alter sugar
absorption.38 Some studies have shown also that Prednisone increased glucose absorption
while other studies resulted in no effect.39 An increase in glucose being transported to the
liver could lead to increased fat accumulation in the liver, which can be another
determinant of NAFLD.
Limited, but current research shows that the ratio of omega-6 fatty acids (n-6) to
n-3 fatty acids may be important in preventing or reducing the metabolic syndrome
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phenotypes such as obesity, NAFLD, dyslipidemia, and insulin resistance observed in
these pediatric patients.40–43
Omega-3 fatty acids play a beneficial function in the reduction of proinflammatory cytokines such as TNF-α and IL-8, reducing the risk of liver disease and
insulin resistance.44 Omega-3 fatty acids may increase anti-inflammatory cytokines by
incorporating n-3 fatty acids into cell membrane phospholipids, which interferes with the
metabolism of linoleic acid (LA), the n-6 precursor to arachidonic acid (AA). Omega-3
and n-6 fatty acids are competitively metabolized by the same enzyme system, therefore,
the PUFA that is most abundant will be preferentially metabolized. When n-3 fatty acids
are most abundant, they will replace AA in the cell membrane and decrease the proinflammatory derivatives of AA. If more n-6 fatty acids are present, then the proinflammatory AA-derived eicosanoids will dominate over the anti-inflammatory n-3
derived eicosanoids. 45 When having a higher dietary intake of n-3 fatty acids, there is an
increase in anti-inflammatory mediators and a decrease in the pro-inflammatory
mediators, which will reduced inflammation and oxidative stress.46
Although considerable research has been devoted to proving the beneficial effects
of GCs as part of the treatment therapy for ALL, few studies have addressed the role of
nutrition, specifically fatty acids, in the reduction of detrimental side effects caused by
chronic GC use.
Certain PUFAs have been advertised as a beneficial component in the diet that
may aid in the reduction of inflammation as well as the decrease in the prevalence of
atherosclerosis, obesity, and diabetes.20 The two major types of essential PUFAs that
demonstrate alterations in the body are n-3 and n-6 fatty acids.47 Dietary n-3 fatty acids
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are commonly found in the forms of essential α-linolenic acid (ALA), eicosapentaenoic
acid (EPA), and docasahexaenoic acid (DHA) and are found in food sources such as fish,
flaxseed oil, and seeds.48,49 These specific forms have been shown to decrease
inflammation by reducing the eicosanoids and other mediators derived from AA.50
Eicosanoid products such as prostaglandins are derived from n-6 fatty acids. Therefore,
the appropriate ratio between n-6 and n-3 fatty acids is critical to produce positive health
effects.51 Common types of dietary n-6 fatty acids are LA and AA, which are found in
nutritional sources such as liquid corn, sunflower, olive, and safflower oils. The westerntype diet characteristically contains low PUFAs with a higher amount of n-6 fatty acids
than n-3 fatty acids. This high ratio of n-6 fatty acids:n-3 fatty acids leads to an increase
in inflammation and issues regarding weight and metabolism.52
Obesity and metabolic disorders have increased over the past decade due to the
increased consumption of a western-type diet, which is high in calories, saturated fat, and
sugar and low in n-3 fatty acids. Pediatric patients undergoing treatment for ALL often
consume foods high in saturated fat, n-6 fatty acids, and sugar before, during, and after
treatment. Increased consumption of these types of foods contributes to the increase in
visceral adipose tissue, NAFLD, insulin resistance, and glucose transporter deregulation,
which are also phenotypes that ALL patients develop.15 However, increasing
consumption of n-3 fatty acids may be able to decrease GC induced health consequences
including the redistribution and increase of adipose tissue, as well as the increase in the
occurrence of inflammation, hypertension, hyperlipidemia, and liver disease.12,53
This information has led to the hypothesis that a western type diet containing high
amounts of fat and carbohydrates will exacerbate the risk of developing metabolic
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syndrome induced by GC treatment. A secondary hypothesis is that the replacement of
lard (higher in n-6 fatty acids) with fish-derived fat (higher in n-3 fatty acids) will reduce
the metabolic disorder phenotypes induced by chronic, long-term exposure to GC and
ultimately reduce the risk for the development of obesity, type 2 diabetes, hypertension,
dyslipidemia, and glucose intolerance.

MATERIALS AND METHODS

Experimental Animals
Newly weaned C57BL/6 male mice were obtained from breeder pairs (purchased
from Harlan Laboratories, Inc., Indianapolis, IN) and housed in a USDA approved animal
facility at the University of Memphis. Mice were weaned to a standard rodent chow diet
(Chow) (6% kcal from fat) or a Western-type diet containing 45% of the calories from fat
(HFL n-6) (45 kcal% fat containing predominantly lard, 41% carbohydrate, 20% sucrose,
9% corn starch, and 12% Maltodextrin 10; Research Diets, Inc., New Brunswick, NJ). At
six weeks of age, mice were separated into individual cages. Mice on the chow diet
remained on the diet, while mice on the HFL diet were randomly divided with half
remaining on the original HFL n-6 and the remainder switched to a diet containing 45%
kcal fat from Menhaden (fish) oil (HFO n-3) for an additional four weeks (Table 1A)
(Research Diets, Inc.). All animals received food and water ad libitum and were
maintained in individual cages with a 12-hour dark/12-hour light cycle. The HFL n-6 and
HFO n-3 diets both contained 45% of kcals from fat. The HFL n-6 diet contains a greater
ratio of n-6 to n-3 fatty acids than the HFO n-3 diet (Table 1B). The HFL n-6 diet also
10

contains a greater amount of Stearic, Oleic, and Linoleic fatty acids than the HFO n-3
diet. The HFO n-3 diet contains a greater composition of Myristic, Palmitoleic,
Stearidonic, Eicosapentaenoic (EPA), Docosapentaenoic, and Docosagexaenoic (DHA),
which are the n-3 fatty acids that have been shown to be beneficial in decreasing
inflammation in the body and decrease the risk of cardiovascular and other metabolic
issues.59 Due to the increase in the n-3 fatty acid components compared to the n-6 fatty
acid components in the HFO n-3 diet, the n-6 to n-3 fatty acid ratio is lower in the HFO
n-3 diet. (Tables 1 A and B).
Mice further received daily doses of the GC Prednisolone or vehicle only for the
final four weeks. Prednisolone was administered at 0.003 grams/mouse/day (40
mg/m2/day) in a vehicle of 0.25g sweet potato. Control mice received 0.25g sweet potato
only. The prednisolone dose given is based on the amount given to pediatric ALL
patients during the induction phase of their therapy. Food intake and body mass were
determined twice weekly. All experiments were conducted in accordance with the
National Institutes of Health Guidelines for the Care and Use of Experimental animals
and were approved by the University of Memphis Institutional Animal Care and Use
Committee.

Table 1. Composition of Experimental Diets. HFL n-6 with 45% kcals/g from lard;
HFO n-3 with 45% kcals/g from menhaden oil. (A) ingredients in HFL-n-6 and HFO n-3
diets; (B) fatty acid composition of HFL n-6 and HFO n-3 diets.
(A)
Ingredients
Casein, 80 Mesh
L-Cystine
Sucrose

HFL n-6
gm (%)
200
3
172.8
11

kcal (%)
800
12
691

HFO n-3
gm (%)
200
3
172.8

kcal (%)
800
12
691

Table 1. Continued
Ingredients
Corn Starch
Maltodextrin 10
Cellulose, BW200
Soybean Oil
Lard
Menhaden Oil (200 ppm tBHQ)
tBHQ
Mineral Mix S10026
Vitamin Mix V10001
Choline Bitartrate
Cholesterol
*BHQ: tertbutylhydroquinone

HFL n-6
gm (%)
72.8
100.0
50
25
177.5
0
0.0355
10
10
2
0.58

kcal (%)
291
400
0
225
1598
0
0
0
40
0
0

HFO n-3
gm (%)
72.8
100.0
50
25
0
177.5
0
10
10
2
0

(B)
Ingredients (g)
Lard
Menhaden Oil, ARBP-F
Soybean Oil
Total
C14, Myristic
C16:1, Palmitoleic
C18, Stearic
C18:2, Linoleic
C18:3, Linolenic, n3
C18:4, Stearidonic, n3
C20, Arachidic
C20:4, Arachidonic, n6
C20:4, n3
C22:5, Docosapentaenoic, n3
C22:5, n6
C22:6, Docosahexaenoic, n3
Total
Saturated (g)
Saturated (%)
Monounsaturated (g)
Monounsaturated (%)
Polyunsaturated (g)
Polyunsaturated (%)
n6 (g)
n3 (g)
n6/n3 ratio

HFL n-6
177.5
0
25
202.5
2.1
2.5
19.8
56.2
4.2
0
0.4
0.5
0
0.2
0
0
190.7
60.2
31.6
67.7
35.5
62.8
32.9
57.0
4.4
13.1
12

HFO n-3
0
177.5
25
202.5
14.0
17.7
6.6
16.1
4.3
6.0
0.3
0
3.1
4.1
0.6
29.0
189.6
59.8
31.5
41.3
21.8
88.5
46.7
17.9
66.6
0.3

kcal (%)
291
400
0
225
0
1598
0
0
40
0
0

Histology
Small intestines were harvested and length measured. Liver and epididymal
adipose tissues were harvested and weighed. A portion of each tissue was fixed in
formalin (Fisher Scientific Co. LLC) embedded in paraffin and 4um sections were
stained with hemotoxylin and eosin. The mean adipocyte area (average surface area of
10-15 randomly selected adipocytes from each mouse (n=6) were determined using
Axiovision r4.8.2 software. Analysis and documentation were performed using an imager
M2 microscope (Axiocam MRC, Zeiss).
Glucose Uptake
Glucose uptake was measured in vitro using the everted sleeve method.60 Briefly,
small intestines were harvested and immediately transferred into cold mammalian 290
mOsm Ringer solution (117 mmol NaCl, 4.7 mmol KCl, 1.2 mmol KH2PO4, 1.2 mmol
MgSO4 and 20 mmol NaHCO3). 1.5 cm long segments were cut starting at the most
proximal region of the intestine. The 1.5 cm segments were everted and secured onto the
ends of a four mm-diameter stainless steel rods using surgical thread to secure the ends.
Mounted tissues were immediately placed in ice-cold 290 mOsm aerated (95% oxygen
and 5% CO2) Ringer solution. Mounted tissue samples were incubated for five minutes in
37°C aerated Ringers solution before being positioned for two minutes over a stir bar
rotating at ~1,200 rpm in a solution of aerated mammalian Ringers solution containing 50
mmol/L D-glucose and a tracer concentration of radiolabeled (14C) D-glucose to
determine D-glucose uptake by the tissues. Radiolabelled (3H) L-glucose was added to
the incubation solution to correct for D-glucose that is associated with the adherent fluid
and passively absorbed.60 At the end of two minutes, tissues were rinsed for 20 seconds
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in cold mammalian ringers solution, removed from the rods, and weight was determined.
The tissues were solubilized (Solvable, Perkin Elmer, Waltham, MA) at 55°C for four
hours, scintillation fluid was added (Ultima Gold, Perkin Elmer, Waltham, MA), and
disintegrations per minute were measured. (Tri-Carb 2900TR, Perkin Elmer, Waltham,
MA). Calculated rates of glucose absorption were expressed as nmoles of D-glucose
transported per minute per mg of tissue.
Metabolic Parameters
Metabolic parameters were determined on days 14 and day 27 after the diet
switch and start of Prednisolone treatment. Fasting blood glucose levels were measured
after mice were fasted for six hours. Glucose was administered at a concentration of
1g/kg of animal weight via an intraperitoneal injection. Blood samples from the tail vein
were collected every 30 minutes for a 90 minutes period. Blood glucose was determined
using a glucose meter (Onetouch Ultra 2 Meter).
Lymphoid Parameters
To determine Prednisolone efficacy, spleens were harvested and weighed.
Splenocytes were isolated and counted using a hemacytometer and trypan blue was used
for dead cell exclusion.
Liver Enzymes
Liver enzymes were measured using an Alanine Transaminase (ALT) Activity
Assay kit (Abcam ab105134). Activity was determined according to manufacturer’s
instructions. Samples were diluted 1:5 in the assay buffer and colorimetric change was
determined after 60-minute incubation and reading at 570nm using a microplate reader
(Synergy 2, BioTek).
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Statistical Analyses
Statistical significance was determined using the Mann-Whitney U test and. p <
0.05 was considered significant.

RESULTS

Diet Containing Fat From Menhaden Oil Reduced Body Mass Gain and
Adiposity Independent of Glucocorticoid Treatment. Mice given a diet containing
45% fat from fish oil (Menhaden oil; major fatty acids EPA and DHA) had reduced body
mass gain over a 28 day period as compared to mice fed an isocaloric diet containing
45% fat from lard, resulting in a significantly reduced body mass at the end of the
experimental period (Figures 1 and 2). The glucocorticoid treatment (Prednisolone) did
not significantly increase body mass gain, regardless of diet treatment.
Mice consuming the diet containing lard averaged an 18% increase in food
consumed in the presence of the glucocorticoids compared to the fish oil diet (Figure 3).
Weight gained per gram of food consumed demonstrated that mice on a fish oil diet gain
30% less weight (without glucocorticoids) and 32% less weight (with glucocorticoids)
compared to mice consuming the lard diet (Figure 4).
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Figure 1. Weight Gain. Weight (grams) was measured weekly over the 28 day period
that the mice received GCs while on a Chow, HFL n-6, and HFO n-3 diet (n= 5-6 mice
for each group).
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Figure 2. Total Weight Gain. Total weight gained was determined at the end of 28 days
for each group. Total weight gained did not differ significantly between the Chow and the
HFO n-3 diet, but there is a significant increase in total weight gain between the HFL n-6
diet and the HFO n-3 diet (P=0.01 in the absence of GC and P=0.03, in the presence GC)
(n=6-9 mice per group).
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Figure 3. Total Food Consumption. Total food consumption was determined by
weekly. In the presence of GC there is not a significant difference in food consumption,
but the consumption of HFL n-6 diet did lead to a significant difference. (P=0.05, n=7-9
mice per group).
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Figure 4. Weight Gained per Gram. GC treatment did not increase the weight gained
per volume of food. There is a significant difference in the amount of weight gained per
volume of food consumed (p=0.02, n=7-9 mice per group) of food consumed in mice on
HFL n-6 or HFO n-3diets with and without GCs.

Glucocorticoid Treatment Reduces Spleen Size Independent of Diet.
Glucocorticoids have become part of the standard treatment for childhood ALL due to its
cytolytic effects on thymocytes. Concomitantly with this decrease in immune cells is a
reduction in immune organs size, including spleens.7 To confirm GC efficacy spleen
weight and spleenocyte number were determined. There was a reduction is spleen size
compared to normal spleen sizes for the chow diet (22% reduction), lard diet (24%
reduction) and fish oil diet (15% reduction; Figure 5). This was also true for splenocyte
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number (Figure 6). Interestingly there was a significant difference in spleen sizes with the
fish oil diet as compared to the chow or lard diet, where the HFO n-3 diets demonstrated
larger spleen sizes, while the HFL n-6 diet show increased cell death independent of
glucocorticoids.
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Figure 5. Spleen Weight. Spleens were harvested and weight determined. There was no
significant difference between groups, but the spleen exposed always tended to be
smaller (N=3-6 mice per group).
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Figure 6. Splenocyte Numbers. Spleens were harvested and splenocytes isolated and
counted using a hemacytometer and Trypan Blue exclusion dye. The P value for Chow
and HFO n-3 with or without GC is 0.057. (n= 3-4 mice per group)

No Difference In Intestinal Glucose Uptake was Observed.
One successful experiment using the sleeve method to measure intestinal glucose
absorption showed no difference in intestinal glucose uptake between mice on lard and
fish oil diet (Data not shown). However, the small intestine lengths of mice fed the HFL
n-6 diet were significantly shorter than those of the chow and HFO n-3 groups (Figure 7).
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Figure 7. Small Intestine Lengths. Lengths measured in cm of mice on chow, HFL n-6,
and HFO n-3 diets.

Liver and histology
Figure 8A demonstrates a significant decrease in liver weight with glucocorticoid
treatment when the animals were on a standard chow diet (P = 0.05). No differences
were observed in liver weight between untreated chow diet and the two high fat diets.
Despite the fact that mice on the high fat diets have similar liver weight independent of
glucocorticoid treatment, there is a dramatic fat deposition in the liver tissue of mice on
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the lard diet by histologic examination. (Hematoxylin-eosin staining; Figure 8B) This fat
accumulation is completely absent in the presence of the fish oil.
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Figure 8. Liver Weight Morphology and Histology. (A) Livers were harvested and
weighed; there was no increase in liver weight with the high fat diets, but GCs caused a
decrease in liver weight when on a Chow diet. (B) Histology revealed an increase in fatty
deposits in the liver (fatty deposit indicated by arrow) when on a HFL n-6 diet, but it is
resolved when mice are switched to a HFO n-3 diet. (20x magnification)
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Plasma Analysis of Liver Parameters was Not Significant.
Plasma Alanine Aminotransferase (ALT) activity was higher in the GC groups for
both the HFL n-6 and HFO n-3 diets. However, the differences in plasma ALT activity
were not significant when comparing the six groups (Figure 9).
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Figure 9. Liver Enzyme Activity. Plasma ALT activity levels were determined and
there were no significant differences between groups (n= 3 mice).
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Adipose Tissue Characteristics and Histology Were Observed for Differences in
Weight and Size.
The weight of the epididymal fat pads reflected the overall weight of the mouse
with the lard diet causing a significant increase in fat deposition as compared to the fish
oil diet (P = 0.01 without glucocorticoid treatment and P < 0.0001 with glucocorticoids
treatment; Figure 10A). As with body mass, glucocorticoids did not increase adipose
tissue weight. However, histologically, there was a significant increase in adipocyte size
in the presence of glucocorticoids only with the lard diet (P = 0.0001; Figure 10B and
10C).
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Figure 10. Adipose Tissue Weight and Morphology. (A) Epidydimal fat pads were
harvested and weighed. Mice on HFL n-6 had significantly larger fat pads, independent
of GC treatment (p=0.0001). (B) Adipocyte morphology (20X magnification)
demonstrate that the HFL diet increased the adipocyte size as compared to the Chow and
HFO diet and that GCs exacerbate this phenotype significantly when on the HFL diet
(p=0.0001).

Plasma Blood Glucose Levels Were Higher in HFL n-6 Diet Mice than HFO n-3 Diet
Mice.
The impact of 40 mg/m2/day of GC administration on glucose tolerance in
correlation with the two different HFDs was assessed with an intraperitoneal glucose
tolerance test (GTT). Our results show that a HFL n-6 diet caused a greater increase in
blood glucose levels compared to the mice on a HFO n-3 diet. (Figure 11 A and B). The
blood glucose levels of the HFL n-6 group with GC administration appeared to be higher
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compared to the HFL n-6 groups without GCs. Figure 11 A and B demonstrates that the
HFO n-3 diets showed similar blood glucose uptake throughout the course of the GTT
regardless of the presence or absence of a GC. Glucose uptake of the HFO n-3 diet group
had similar levels to the chow diet group (data not shown).
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Figure 11. Glucose Tolerance test. (A) Blood glucose concentration (mg/dl) was
measured over 90 minutes. (B) At 90 minute after glucose (1g/kg) administration,
glucose levels were increases with the HFL n-6 diet and trended trend towards glucose
intolerance (p=0.06) (n=3-5 mice per group).
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DISCUSSION

Patients undergoing ALL treatment (which includes high dose GCs) have an
increased risk of developing metabolic syndrome later in life.14,61,62 Pediatric survivors
typically demonstrate signs of obesity, insulin resistance, dyslipidemia, and hypertension
in remission from ALL indicating that GCs may have long term side effects even after
therapy.14,62 These side effects may be due to GCs main role in decreasing inflammation
by suppressing the immune system and controlling energy metabolism, especially hepatic
energy metabolism.
GCs have a role in ALL treatment due to their anti-inflammatory and cytolytic
effects.8 As GCs reduce immune cells, there is a concomitant reduction in the mass of
immune organs. The significant decrease in spleen weights and spleen cells confirmed
that GCs had a similar effect on immune cells and associated organs during the 28-day
treatment.
Due to the unquestionable evidence of dietary intervention on human health, we
focused our efforts on the effects of a diet high in n-6 fatty acids from lard compared to a
diet high in n-3 fatty acids from fish oil. Our results mirrored data from a previous study
reporting that animals consuming a diet high in n-3 fatty acids had less total adipose
tissue, intra-abdominal fat, and less insulin resistance than a animals consuming a high
fat lard diet. 63 The mice in the present study showed that the HFL n-6 diet promoted
more overall weight gain, adipose tissue gain, more food consumption, and more weight
gain per gram food than the mice on the HFO n-3 diet. This is in accordance with
published work demonstrating that a diet high in EPA and DHA upregulate fatty acid
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oxidation suggesting that the n-3 fatty acids may be protective against adipose tissue
gain. It is now well established that n-3 fatty acids in fish oil increases fatty oxidation
while the n-6 fatty acids from lard induces the expression of transcription factors that
regulate lipid homeostasis such as Sterol Regulatory Element Binding Protein (SREBP),
which promotes fatty acid synthesis.64 The result of the weight gained by the mice
demonstrates that the type of diet has a greater effect on weight gain than the presence of
GCs.
Histological evaluation of the epididymal fat showed that the adipocytes from the
HFL n-6 diet were larger in diameter compared to both the HFO n-3 and Chow diets. The
adipocytes on the chow and HFO n-3 diet were similar in size, indicating that the n-6
fatty acids in the lard diet may alter physiological mechanisms that increase the size of
the adipocytes. Moreover, the administration of glucocorticoids caused a significant
increase in adipocyte size, but only when mice were exposed to the n-6 lard diet.
Long-term use of GCs can cause NAFLD due to alterations in hepatic
metabolism.4 NAFLD results from a combination of insulin resistance and an increase in
the uptake of free fatty acids and de novo liponeogeneisis in the hepatocytes leading to an
accumulation of stored fat in the liver.4 Although there were no histological differences in
fatty deposition in the liver between the HFL n-6 with and without GCs, ALT enzymes
were increased in the HFD groups with GCs, albeit not significantly. This may indicate
that the GCs could be causing liver damage, however, liver damage indicated by elevated
plasma ALT levels and fibrosis, typically does not develop with less than four weeks of
high fat feeding.65–67 A longer time on the HFD may be needed to see more true liver
damage as indicated by increased ALT enzymes. The histological results of the livers
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show that the HFL n-6 diet caused more fat accumulation than the chow or HFO n-3
diets, which could further develop into more liver damage with a longer study period on
the HFD indicated by high ALT enzyme levels and liver fibrosis. Therefore, the HFO n-3
diet may be protective and decrease the risk of NAFLD.
Similar to other findings where hyperglycemia was seen in a HFD in conjunction
with a GCs, the data from the GTT’s throughout our study demonstrates that the HFL n-6
diet rapidly induced a type 2 diabetic phenotype after four weeks on the diet.15 This was
characterized by glucose intolerance as measured by an intraperitoneal glucose tolerance
test over 90 minutes. Due to the research that shows that insulin resistance could lead to
NAFLD, a longer study period could show more data that demonstrates the development
of NAFLD68.
Fatty acids in the liver can alter glucose metabolism, therefore we evaluated
possible alterations in intestinal uptake of glucose by the inverted sleeve method to
determine if there is an alteration in glucose uptake in the presence of the different fatty
acid composition in the diet. 69 Due to controversial research regarding the fluctuation of
glucose transporters in the small intestines, we measured rates of glucose uptake by the
small intestines of mice fed the HFL n-6 diet and the HFO n-3 diet. The data suggested
that glucose uptake of the small intestine is not affected by the type of diet consumed
during the seven weeks on the diet. However, there was a significant decrease in
intestinal length of mice consuming the HFL n-6 diet as compared to the mice consuming
a chow and HFO n-3 diet. However, the small intestines in both HFD groups showed to
have similar glucose absorption rates, indicating that the number of transporters was most
likely the same in the proximal areas of the intestines. However, the differences in the
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intestinal lengths could possibly indicate that chow and HFO n-3 diet mice could have
more glucose uptake capacity than the HFL n-6 diet mice. Further understanding of why
a diet high in n-6 fatty acids could cause a decrease in intestinal size and yet, still advance
to obesity and insulin resistance will need to be rendered.

CONCLUSION

This study demonstrates that a high fat diet higher in n-6 fatty acids can lead to
detrimental side effects, especially in combination with GC therapy. Here we show that a
diet high in n-6 fatty acids increases total body and adipose tissue weight, per volume of
food consumed. In addition, the data shows that a HFL n-6 diet in the presence of 40
mg/m2/day prednisolone increases fatty liver development and insulin resistance.
However, the replacement of a HFL n-6 diet with a HFO n-3 diet will reduce the
metabolic disorder phenotypes, specifically hyperglycemia, obesity, and liver disease to
similar phenotypes of animals consuming a chow diet during glucocorticoid treatment.
The results suggests that a diet high in n-6 fatty acids may be beneficial for
pediatric ALL patients undergoing GC treatment and might decrease the risk of
developing symptoms associated with metabolism after their treatment.
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APPENDIX

A. IACUC Approval
IACUC PROTOCOL
FOR USE OF LIVE VERTEBRATES FOR RESEARCH, TEACHING OR DEMONSTRATION

UNIVERSITY OF MEMPHIS

Date Submitted to IACUC 7/21/14

IACUC Protocol #

Dates Protocol will be in effect:

from

8/19/14

to 5/31/16

(not to exceed three years including two yearly renewals)

Is this protocol related to an external grant or contract application? Yes

No X

If yes, complete the following:

Agency:

Date Submitted

Grant #

University account for Animal Care Facility per diem charge:

If the protocol is not related to an external grant or contract application, complete
the following:

University account for Animal Care Facility per diem charge:
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211700

Effect of a dietary intervention on glucocorticoid-induced metabolic syndrome.

Project Title: (If project relates to a grant or contract application, give that title; if the
project is related to a class, give the course name and number):

I. Personnel

Investigator/Instructor:

Marie van der Merwe

Department: Health and Sport Sciences

Academic Rank: Assistant Professor

Campus phone: 901 678 3476

Emergency phone: 901 406 7458

Attending Veterinarian: Karyl Buddington

Phone:

Emergency phone:

901 678 2359

901 258 1232

List all individuals that will handle animals using this protocol and their level of
expertise (e.g. relevant qualifications). If the protocol applies to a class then so specify.
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Marie van der Merwe – PhD (Molecular Pharmacoly), Postdoctoral Fellowship (Bone
Marrow Transplantation): More than 10 years of experience using mice as a research
model.

Simone Godwin – BA (Anthropology), Animal husbandry internship at Duke Lemur Center
(Durham), Primate conservation and rehabilitation internship at Alouatta Sanctuary
(Panama)

LeeAnna Beech – B.S (Dietetics), A.S (Science), Animal trainer certification at Dolphin
Quest (O’ahu)

If additional personnel become involved in handling animals used in this protocol,
it is the responsibility of the principal investigator to notify the Animal Care
Facility in writing before they start.
If applicable, has the investigator/instructor and all personnel listed above
received the appropriate vaccinations (tetanus, rabies)?

Yes

Is it necessary for personnel listed on this protocol to be tested for TB? Yes

No
No X

If you have questions about the kind of vaccination or about TB, call the Animal
Care Facility at 678 2034.
All U of M personnel involved in this protocol must complete the animal care and
use training program (satisfactory completion of, or concurrent registration in Biol
7006/8006), or have completed a comparable training program at another
institution before animals can be procured or before the experiments/teaching or
demonstration. In submitting this protocol, I, as Principal Investigator/Instructor
accept the responsibility for compliance with this requirement.
In addition, the Principal Investigator/Instructor must be willing to provide
appropriate supervision for all persons working on this protocol. In the case of a
class, the Instructor must be responsible for training any students in classes
involved prior to using animals.
II.

Project Description

A. Summary (Enter a brief description below of your project, using lay
terminology):
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Acute lymphoblastic leukemia (ALL) treatment increases the risk for pediatric patients to
develop obesity and symptoms similar to metabolic syndrome including type-2 diabetes and
dyslipidemia. The treatment includes many chemotherapies and also high doses of
glucocorticoids. The long term use of glucocorticoids has been associated with the
increases in weight and also symptoms similar to metabolic syndrome. The goal of this
experiment is to determine if dietary interventions can reduce risk and long term
consequences associated with the use of glucocorticoids.

We will use a mouse model (C57BL/6) that will receive a 45% fat (lard) diet, similar to a
Western diet. Control mice will be on a “normal” 10% fat diet. As an intervention, the fat
source will be altered to a 45% fish oil diet (omega-3 fatty acids). Omega-3 fatty acids have
been shown to reduce inflammation and decrease risk of development of glucose
intolerance. While on the various diets, mice will be given the glucocorticoid, prednisone at
a dose of 40mg/m2/day for 28 days. Prednisone will be administered orally using a vehicle
on a daily basis. 28 days reflect the induction phase of ALL treatment during which time
the patients receive high doses of prednisone and experience a dramatic increase in weight.

Eating habits (amount of food consumed) and weights of mice will be monitored twice a
week. After two weeks (14 days), half of each group of mice will be anaesthetized to
perform a DEXA scan (whole body fat composition) Blood will be drawn to determine
glucose and insulin levels. A glucose tolerance test will be performed by administering
glucose and then measure glucose levels in blood at various time points. The mice will be
sacrificed to harvest brain, adrenal glands, liver, spleen, mesenteric lymph nodes and
adipose tissue for analysis. The remainder of the mice will go through the same process at
28 day after the start of glucocorticoid treatment.

B. Describe IN DETAIL the procedures you will follow. You may do this in either of
two
ways (Check one of the options below and follow the associated instructions):
1. Accompanying documentation (include documentation in box below).
X OR
2. By reference to previously published work (provide a complete bibliographic
citation in the box below, and describe any variations from the published
technique).
44

Mice: C57BL/6 male mice will be used for this study and obtained from breeder pairs that are bred and
housed at the animal facility on the University of Memphis campus.
Diets and treatments: All of the mice will be weaned at 3 weeks of age to the western diet with 45%
lard and 41% carbohydrate (20% sucrose, 9% corn starch and 12% Maltodextrin 10). For Specific Aim
1 the mice will remain on this diet. For Specific Aim 2 the lard component will be replaced using fish
oil at the start of glucocorticoid treatment to provide the long chain omega-3 fatty acids. The diets will
be purchased from Research Diets, which has experience in producing the western diet for rodent
studies.
Glucocorticoid therapy: To resemble the age group of ALL patients treated at St Jude, mice will be 6
weeks of age at the start of glucocorticoid therapy. Mice of this age are comparable to a 4 year old
child. The glucocorticoid treatment will last for 28 days. Prednisone (40 mg/m2/day) will be orally
administered on a daily basis by adding it to a vehicle of canned sweet potato or other canned fruits or
vegetables. If the vehicle is not sufficient to mask the taste of prednisone, we might use prednisolone
that is bioequivalent to prednisone, but is more palatable. This might only be needed for the first
couple of doses as the increase of appetite drivel by the glucocorticoid might drive the consumption of
the drug in vehicle. If prednisolone is not efficiently consumed, we will administer the drug by gavage.
Again, this might only be required for the first couple of days until their appetite increases.
Experimental design:
For Specific Aim 1, 40 male mice will be divided into 2 experimental groups, with all mice fed the
western diet with lard and with or without the addition of the glucocorticoid (GC) treatment
(20/group). Half of each group - 10 mice – will only be treated for 14 days. This group will be
anaesthetized (isoflurane) after a 10 h fast, a DEXA scan performed (anesthetized for 15 min) and
blood collected via the saphenous vein in one of the back legs to determine fasting glucose and insulin
levels and also determine cytokine levels. For the glucose tolerance test, these mice will be given a 1g
glucose/kg body weight intraperitoneally and blood collected every 30 minutes for 90 minutes to
measure glucose levels. Mice will then be euthanized (CO2 inhalation) to collect brain, adrenal glands,
liver, spleen, mesenteric lymph nodes and adipose tissue for histology, biochemistry and immune cells
harvest. This data will reveal if there is any early indication of the metabolic phenotype. The remainder
of the mice will remain on the glucocorticoid treatment for another 14 days at which point this group
will be anaesthetized (isoflurane) after a 10 h fast, a DEXA scan performed and blood collected via the
saphenous vein in one of the back legs to determine fasting glucose and insulin levels and also
determine cytokine levels. For the glucose tolerance test, these mice will be given a 1g glucose/kg
body weight intraperitoneally and blood collected every 30 minutes for 90 minutes to measure glucose
levels. Mice will then be euthanized (CO2 inhalation) to collect brain, adrenal glands, liver, spleen,
mesenteric lymph nodes and adipose tissue for histology, biochemistry and immune cells harvest.
The same experimental approach will be used for Specific Aim 2, except the lard diet will be replaced
by the fish oil based western diet.
Specific Aim Western Diet type
1 (n = 40)

Lard

2 (n = 40)

Fish Oil

Treatment
Plus Glucocorticoid No Glucocorticoid

Plus Glucocorticoid No Glucocorticoid
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The goal of this experiment is to mimic the metabolic syndrome that is induced in the
pediatric population treated for acute lymphoblastic leukemia. No restriction or dietary
advice is currently given to these patients. We are interested in the kinetics of the onset
of the syndrome and also what role the immune system plays is setting up the
environment for the disorder.

The C57BL/6 diet induced obesity (dio) mouse model has been used previously to look
at the effect of excess weight on various organ systems. As we are interested in the
interaction between the immune system and other organs and what role it plays in the
onset of metabolic phenotype, we cannot use isolated cell lines or model organisms such
as yeast. Additionally, many reagents have been developed for the use of mouse tissues,
especially antibodies that will be used to identify immune populations.

There will be 10 mice per group for each time point. This number should be sufficient to
determine statistical significance. (There will also be 16 mice on regular chow to use as
controls.)

C.
Rationale for Involving Animals and the Appropriateness of Species and
Number Used.
Indicate (here) briefly the short and/or long-term benefits (to humans and/or other
animals) of this use of animals for research, teaching or demonstration. In addition,
state briefly why living animals are required for this study, rather than some alternative
model.

D. Do the procedures described in B above, have the potential to inflict more than
momentary pain or distress (this does not include pain caused by injections or other
minor procedures)? Yes
No X
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If yes, please address the following:
I have considered alternatives to procedures that might cause more than momentary or
slight pain/distress, and I have not found such alternatives. As such, I have used one or
more of the following methods and sources to search for such alternatives: (check below
each method used)
Agricola Data Base

Medline Data Base

CAB Abstracts

TOXLINE

BIOSIS

Lab. Animal Sci.

Lab Animal

Animal Welfare Info

Journal
Lab. Animals Journal
Center
ATLA (Alternatives to Laboratory Animal Journal)
Lab Animal Welfare Bibliography (QL55L27311988)

Quick Biblio. Series
"Benchmarks"

"Alternatives to Animal Use in Research, Testing and Education"
Current Contents
CARL
Direct contact with colleagues (if selected, you MUST document this below)
What is the length of time that the literature search covers
III.

Animal Use

A. List all animal species to be used (example below).
Species Number1

Age2

Sex

Weight2

Hooded Wistar rats

45

2 months

male

250-350 gm

C57BL/6 mice

96

2 months

Male

20-25 gm

1

(Bldg./Rm#)
Psychology
Bld./422I
Psychology
Bld./422I

Individuals using ectotherms need to only approximate numbers.
Individuals using fish or other ectotherms need not answer this question.

2
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Is any species threatened or endangered?

Yes

No X

B. Source of animals
X Commercial vendor (Source: Jackson Labs) Female mice will be purchased to breed
with male mice available on the UM campus
X Bred at The University of Memphis
Captured from wild
Transferred from another study (IACUC) Protocol Number
Donated (Source)
Tennessee Wildlife Resources Agency
Purchased and supplied by TMGC
Is the supplier a USDA approved source?

Yes

No

Yes

No

If not, explain why:
Animals are already in residence at U of M
C. Will surgery be conducted on animals?
If yes, complete this section:
Non Recovery Surgery

Recovery Surgery

Multiple Survival Surgery (if the latter is checked, complete section F)
Surgeon(s) (Name/Job/Title/Academic Rank
D.

Location of Surgery (Bldg. & Room #)

Will Anesthetic(s), Analgesic(s), or
Yes X

Tranquilizing agents be administered?

No

If yes, complete this section (example below).
Species & Sex

Agent

male Hooded
Wistar rats

sodium
pentobarbitol

C57BL/6 mice

Isoflurane

Dose Route Performed by (Name/Title/Academic Rank)
50 mg/kg
2-4%
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i.p.

Mr. Smith/Research Technician/B.Sc.

Inhalation

Marie van der Merwe/ Assistant
Professor
Simone Godwin/Masters Student
LeeAnnaBeech/Masters Student

E. Will euthanasia be carried out?

Yes X

No

If yes, complete this section (example below).
Species & Sex Agent Dose

Route

Performed by (Name/Title/Academic Rank)

male Hooded

sodium

150

Wistar rats

pentobarbitol

mg/kg

C57BL/6 mice

CO2

3L/min

i.p.

Mr. Smith/Research
Technician/B.Sc.

Inhalatio
n

Marie van der Merwe/ Assistant
Professor
Simone Godwin/Masters Student
LeeAnnaBeech/Masters Student

If no, describe disposition of animal(s) at conclusion of this study in box below.

F.

Will special housing, conditioning, diets or other conditions
be required?

Yes X

No

Mice will be on special high fat (either lard/fish oil) diets in addition to receiving daily
oral glucocorticoids.
If yes, please explain in box below.

G. Will animals be removed from the U of M campus at any time? Yes

No X

If yes, please indicate to where and for how long in box below.

G. If they are to be housed for more than 24 hours outside approved facilities at U of
M, provide a scientific justification in box below
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IV.

Toxic and Hazardous Substances

A. Check off any of the following below that will be used in these experiments?
Infectious agents (Fill out a, b)
Radioisotopes (Fill out a, b, e)
Toxic chemicals or carcinogens (Fill out a, b)
Recombinant DNA (Fill out a)
Experimental drugs (Fill out a)
Malignant cells or hybridomas (Fill out a, c)
Adjuvants (Fill out a)
Controlled substances (Fill out a, d, e)
For each checked off category, answer the questions indicated below:
a. Identify the substance(s) and completely describe their use, including how will be
injected or given to the animal(s):
b. Describe all procedures necessary for personnel and animal safety including
biohazardous waste, carcass disposal and cage decontamination:
c.
If transplantable tumors or hybridoma cells are to be injected into the
animals, have the tissues/cells been tested for inadvertent contamination by viruses or
mycoplasma?
Yes
No

d. In the box below, provide a complete list of these substances, and if their use is not
explicitly explained in the materials already provided, explain their use and role in the
research.
Provide DEA license # covering the use of these substances:
To whom (or what entity) is the license issued?
e.

Provide Radioisotope License Number:

To whom is the license issued?

V. Categories of Animal Experimentation Based Upon Level of Manipulation and
Pain: (check off each category that is applicable to this application)
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X A.

Animals will be involved in teaching, research, experiments or tests involving
no pain, distress, or use of pain-relieving drugs.

X B.

Animals will be subject to mild stress only (e.g., food or water deprivation of
less than 24 hours for use in behavioral studies such as operant
conditioning; physical restraint for less than 30 minutes), and will not be
subject to surgery, painful stimuli, or any of the other conditions described
below. Procedures described in this protocol have the potential to inflict no
more than momentary or slight pain or distress on the animal(s)----that is,
no pain in excess of that caused by injections or other minor procedures
such as blood sampling.

X C.

Animals will have minor procedures performed, blood sampling, etc. while
anesthetized.

X D.

Live animals will be humanely killed without any treatments, manipulations,
etc. but will be used to obtain tissue, cells, sera, etc.
E. Live animals will have significant manipulations, surgery, etc. performed
while anesthetized. The animals will be humanely killed at experiment
termination without regaining consciousness.
F. Live animals will receive a painful stimulus of short duration without
anesthesia (behavior experiments with flight or avoidance reactions--e.g.,
shock/reward) resulting in a short-term traumatic response. Other examples
in this category are, blood sampling, injections of adjuvants, or drugs, etc.
G. Live animals will have significant manipulations performed, such as
surgery, while anesthetized and allowed to recover. Such procedures cause
post-anesthetic pain/discomfort resulting from the experiment protocol (e.g.,
chronic catheters. surgical wounds, implants) which cause a minimum of
pain and/or distress. Also included are mild toxic drugs or chemicals, tumor
implants (including hybridomas). tethered animals, short-termed physically
restrained animals (up to 1 hour), mother/infant separations.
H. Live animals will have significant manipulations or severe discomfort, etc.
without benefit of anesthesia, analgesics or tranquilizers. Examples to be
included in this category are: toxicity testing, radiation sickness, irritants,
burns, trauma, biologic toxins, virulence challenge, prolonged: restrictions
of food or water intake, cold exposure, physical restraint or drug addiction.
All use of paralytic agents (curare-like drugs) must be included in this
category. Describe any abnormal environmental conditions that may be
imposed. Describe and justify the use of any physical restrain devices
employed longer then 1 hour.
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VI. Justifications for Category G Studies and Deviations from Standard
Techniques
Describe in the box below any steps to be taken to monitor potential or overt pain and/or
distress during the course of this study and how such pain or distress will be alleviated.
Be as detailed as necessary to justify your procedure.

VII. Certifications
(By submitting this protocol, I am acknowledging that I comply with the
certifications included in Section VII.) (check one)
X Animal Use for Research. I certify that the above statements are true and the protocol
stands as the original or is essentially the same as found in the grant application or
program/project. The IACUC will be notified of any changes in the proposed
project, or personnel, relative to this application, prior to proceeding with any
animal experimentation. I will not purchase animals nor proceed with animal
experimentation until approval by the IACUC is granted.
Animal Use for Teaching/Demonstration. I certify that the information in this
application is essentially the same as contained in the course outline and a copy of
the laboratory exercises using animals is on file in the IACUC office. The IACUC
will be notified of any changes in the proposed project, or personnel, relative to
this application, prior to proceeding with any animal experimentation. I will not
proceed with animal experimentation until approval by the IACUC is granted.
Estimate the cost of maintaining animals used in this protocol based on current per diem
charge at University of Memphis.
$ 24/day (24c/cage/day)
Please specify cost per unit of time:

Specify anticipated total costs for project duration:

$ 1680

As supervisor of this project it is required that you inform your department chair
concerning any animal per diem costs related to this project that are to be paid by
the department.
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By submitting this protocol, the Principal Investigator/Course Director indicates
that the following have been considered:
1. Alternatives to use of animals.
2. Reduction of pain and stress in animals to the lowest level possible.
3. The proper needs of the animals with respect to housing and care.
4. The lowest number of animals used that will give the appropriate experimental results.
5. Use of the most primitive species that will give the appropriate experimental results.
6.

Proper training of all personnel in the care and handling of the species used and in
the procedures called for in this protocol before beginning the
experiment/teaching or demonstration.

7. That this protocol is not an unnecessary repeat of results already in the literature or in
the case of teaching/demonstrations, results that can be demonstrated using
models or video material.

Principal Investigator/Course Director (Type Name)

e-mail address

Date

Marie van der Merwe

mvndrmrw@memphis.edu

7/21/14

Federal Law requires that members of the IACUC be given adequate time to read and
review protocols including any changes or revisions in them.
The University of Memphis IACUC evaluates protocols on a continuous basis. Any
protocols or modifications or renewals to any protocols to be considered at this time
must be received by the Animal Care Facility no later than the end of the second week of
the previous month.
Incomplete protocols will be returned to the principal investigator. We will not accept a
FAXed protocol, renewal form or changes to a protocol.
E-mail the completed protocol to Dr. Guy Mittleman (Dept. Psychology):
mailto:<g.mittleman@mail.psyc.memphis.edu>?subject=RE: IACUC Application
January, 2008
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